Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of long-acting interferon guided by ΔHBsAg in HBeAg-negative chronic HBV infection
ChiCTR2400082602Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xinjiang Medical University
- Start
- Apr 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) and Chronic hepatitis B (CHB) (4 arms), sponsored by First Affiliated Hospital of Xinjiang Medical University. Primary endpoints: HBsAg clearance rate and HBsAg seroconversion rate. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)Chronic hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2400082602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082602.